Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Google Secures Pentagon AI Deal for Classified Projects 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
DURHAM, N.C., April 26, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced today that Jeff Wolf, Heat’s Founder and CEO, will present at PIONEERS 2017, presented by Joseph Gunnar & Co., on Tuesday, May 2, 2017, at 11:30 a.m. ET. The event will be held at the Mandarin Oriental Hotel in New York City.
Management will be available to meet with investors during the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Joseph Gunnar & Co. representative, email [email protected] or email [email protected].
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that robustly activates the immune system. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.
For more information, please visit www.heatbio.com.
For Investor Inquiries: David Waldman 919-240-7133 [email protected] For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 [email protected]
